MGMT Promoter Methylation and Parathyroid Carcinoma
| Autor: | Camilla Schalin-Jäntti, Tiina Vesterinen, Eeva Ryhänen, Ilkka Heiskanen, Johanna Arola, Jukka Schildt, Auli Karhu, Sara Storvall, Soili Kytölä, Frank V. Bensch |
|---|---|
| Přispěvatelé: | Endokrinologian yksikkö, HUS Abdominal Center, University of Helsinki, Department of Medicine, II kirurgian klinikka, HUSLAB, Department of Pathology, HUS Medical Imaging Center, Clinicum, Department of Diagnostics and Therapeutics, University Management, Genome-Scale Biology (GSB) Research Program, Department of Medical and Clinical Genetics, Lauri Antti Aaltonen / Principal Investigator, ATG - Applied Tumor Genomics, Research Programs Unit |
| Rok vydání: | 2019 |
| Předmět: |
MGMT promoter methylation
Parathyroid Bone and Mineral Metabolism Endocrinology Diabetes and Metabolism education 3122 Cancers 030209 endocrinology & metabolism Context (language use) temozolomide Neuroendocrine tumors 03 medical and health sciences 0302 clinical medicine Promoter methylation medicine Clinical Research Articles Parathyroid adenoma Temozolomide treatment business.industry Methylation parathyroid carcinoma 3126 Surgery anesthesiology intensive care radiology medicine.disease digestive system diseases 3. Good health Parathyroid carcinoma 3121 General medicine internal medicine and other clinical medicine 030220 oncology & carcinogenesis Cancer research business Primary hyperparathyroidism medicine.drug |
| Zdroj: | Journal of the Endocrine Society |
| ISSN: | 2472-1972 |
| DOI: | 10.1210/js.2019-00175 |
| Popis: | Context Parathyroid carcinoma (PC) is extremely rare. Prognosis is poor, with no known evidence-based systemic therapies. We previously reported complete remission in a patient with metastasized parathyroid carcinoma and high tumor MGMT promoter methylation status who was treated with temozolomide. Objective To study MGMT promoter methylation status in an additional set of aggressive parathyroid tumors. Design/Setting The study included 12 patients: 7 with sporadic and 5 with familial primary hyperparathyroidism (two of the latter carried a CDC73 gross deletion). Patient 9 is the previously described patient with PC and high MGMT methylation status. Her daughter (patient 12) had surgery for severe primary hyperparathyroidism due to atypical parathyroid adenoma during pregnancy. Eleven patients thus had PC and one had atypical parathyroid adenoma. MGMT promoter methylation status was determined from DNA extracted from primary (n = 10) or metastatic (n = 2) tumors. A mean methylation level >20% was considered high. Patient 11 had metastatic PC and received temozolomide cycles. Results Only the previously published patient (patient 9) had high tumor MGMT promoter methylation status. This was not a characteristic of the atypical parathyroid adenoma of the daughter (patient 12). Patient 11 (CDC73 intragenic deletion) has disseminated PC, low MGMT promoter methylation, and stable disease on follow-up after temozolomide treatment. Conclusion High MGMT promoter methylation status seems rare in PC. However, as demonstrated in other neuroendocrine tumors, some patients with disseminated PC might benefit from temozolomide. Demonstration of high methylation status could be a predictor of positive response to temozolomide treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|